Reversal of cognitive decline: A novel therapeutic program
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND). The first 10 patients who have utilized this program include patients with memory loss associated with Alzheimer's disease (AD), amnestic mild cognitive impairment (aMCI), or subjective cognitive impairment (SCI). Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months, with the one failure being a patient with very late stage AD. Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance. Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement. These results suggest that a larger, more extensive trial of this therapeutic program is warranted. The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes. Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992 · cited 1×
“In support of this model, the four peptides derived from the amyloidogenic processing of β-amyloid precursor protein (APP)—sAPPβ, Aβ, Jcasp, and C31—have been shown to mediate neurite retraction, synaptic inhibition, caspase activation, and programmed cell death [6, 10-12]; whereas, in contrast, the two peptides deriv…”
MethodRetractedHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Exercise builds brain health: key roles of growth factor cascades and inflammation
Cotman, C. W., Berchtold, N. C., & Christie, L.-A. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.011 · Cited by 2,268 · cited 1×
“There are numerous physiological parameters that feed into this balance, such as hormones [28, 29], trophic factors [18], glucose metabolism [30], inflammatory mediators [31], ApoE genetic status [32] sleep-related factors [33], exercise-related factors [34], and many others; therefore, the therapeutic system is desig…”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“Reducing this ratio, whether by affecting BACE (β-site APP cleaving enzyme) or other cleavage of APP, appears to mitigate the AD severity [7, 16, 17].”
BackgroundExogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 1×
“Moreover, Aβ itself has been shown to exhibit prionic properties [21], although the mechanism by which it does so has not been clarified.”
BackgroundSmith, G. E., Housen, P., Yaffe, K., Ruff, R., Kennison, R. F., Mahncke, H. W., & Zelinski, E. M. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02167.x · Cited by 785 · cited 1×
“Exercise 30-60’ per day, 4-6 days/wk [37, 38] Brain stimulation Posit or related [39] Homocysteine <7 Me-B12, MTHF, P5P; TMG if necessary [40]”
Begum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., Heath, D. D., Rock, C. L., Pruitt, M. A., Yang, F., Hudspeth, B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137455 · Cited by 604 · cited 2×
“[36] Exercise 30-60’ per day, 4-6 days/wk [37, 38] Brain stimulation Posit or related [39] Homocysteine <7 Me-B12, MTHF, P5P; TMG if necessary [40] Serum B12 >500 Me-B12 [41] CRP <1.0; A/G >1.5 Anti-inflammatory diet; curcumin; DHA/EPA; optimize hygiene Critical role of inflammation in AD Fasting insulin <7; HgbA1c <5…”
BackgroundInfluentialSehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390 · cited 2×
“[36] Exercise 30-60’ per day, 4-6 days/wk [37, 38] Brain stimulation Posit or related [39] Homocysteine <7 Me-B12, MTHF, P5P; TMG if necessary [40] Serum B12 >500 Me-B12 [41] CRP <1.0; A/G >1.5 Anti-inflammatory diet; curcumin; DHA/EPA; optimize hygiene Critical role of inflammation in AD Fasting insulin <7; HgbA1c <5…”
BackgroundInfluentialEstrogen use, APOE, and cognitive decline: Evidence of gene–environment interaction
Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000) · Neurology · doi:10.1212/wnl.54.10.1949 · Cited by 371
Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509695103 · Cited by 239
Self-citation
Cited by
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Metabolic profiling distinguishes three subtypes of Alzheimer's disease
Bredesen, D. E. (2015) · Aging · doi:10.18632/aging.100801 · Cited by 76
Self-citationPapadaniil, C. D., Kosmidou, V. E., Tsolaki, A., Tsolaki, M., Kompatsiaris, I. (., & Hadjileontiadis, L. J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.07.043 · Cited by 71
Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy
Nehls, M. (2016) · Journal of Molecular Psychiatry · doi:10.1186/s40303-016-0018-8 · Cited by 41
“This assumption is in line with the results from a recent study conducted by Dale Bredesen where 8 of the 10 patients that represented with stage 1 (3 patients), stage 2 (2 patients) and stage 3 (3 patients) recovered their episodic memory after adhering to a similar therapeutic scheme as it results from the UTAD (see…”
ResultMicrobiome restoration diet improves digestion, cognition and physical and emotional wellbeing
Lawrence, K., & Hyde, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179017 · Cited by 34
“Interestingly, the dietary protocol of The Gut Makeover is very similar to that included in a multi-dimensional therapy used by Bredesen [46,47] for patients in the early stages of Alzheimer’s disease.”
MethodRetractedDaulatzai, M. A. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9528-x · Cited by 12
“Pragmatically, therefore, a host of pathologies will require a host of correspondingly appropriate treatment strategies/modalities (Chan et al. 2012; Bredesen 2014).”
Background
Metadata
- Authors
- Bredesen, D. E.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2014-09-27
- Volume
- 6
- Issue
- 9
- Pages
- 707-717
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W2161039995
- Cited by
- 227
- References
- 15
- FWCI
- 16.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.